Listed

Cytek Biosciences, Inc.

CTKBNasdaqCIK 1831915TechnologyFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$48.1mRevenue, Q2 FY2026, three months to 2026-06-30$48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$48.1mRevenue, Q2 FY2026, three months to 2026-06-30$48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure+5.6% on a year earlier
  • Gross margin58.9%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $28.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Revenue: $48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure+6.5 pts on a year earlier
  • Operating margin−23.7%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$11.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Revenue: $48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure−0.4 pts on a year earlier
  • Net margin−25.3%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$12.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Revenue: $48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure−13.0 pts on a year earlier
  • Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
  • Free cash flow−$849.0kFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053496. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001628280-26-053496. Derived: 6-month figure less the 3-month figure.Report this figure+42.2% on a year earlier

Last eight quarters

Full statements
Revenue$48.1mGross margin 58.9%
Free cash flow−$849.0k, Q2 FY2026
Cytek Biosciences, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m51.5Revenue, Q3 FY2024, three months to 2024-09-30$51.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Report this figure57.5Revenue, Q4 FY2024, three months to 2024-12-31$57.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Report this figure41.5Revenue, Q1 FY2025, three months to 2025-03-31$41.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Report this figure45.6Revenue, Q2 FY2025, three months to 2025-06-30$45.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure52.3Revenue, Q3 FY2025, three months to 2025-09-30$52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Report this figure62.1Revenue, Q4 FY2025, three months to 2025-12-31$62.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Report this figure44.1Revenue, Q1 FY2026, three months to 2026-03-31$44.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Report this figure48.1Revenue, Q2 FY2026, three months to 2026-06-30$48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure
Gross margin%56.3%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $29.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Revenue: $51.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Report this figure58.5%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $33.7m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Revenue: $57.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Report this figure48.6%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $20.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Revenue: $41.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Report this figure52.3%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $23.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Revenue: $45.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure52.7%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $27.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Revenue: $52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Report this figure52.9%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $32.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Revenue: $62.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Report this figure48.2%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $21.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Revenue: $44.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Report this figure58.9%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $28.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Revenue: $48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure
Operating margin%(8.2%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$4.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Revenue: $51.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Report this figure5.2%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $3.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Revenue: $57.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Report this figure(36.1%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$15.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Revenue: $41.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Report this figure(23.3%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$10.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Revenue: $45.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure(17.6%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$9.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Revenue: $52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Report this figure(9.0%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$5.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Revenue: $62.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Report this figure(41.8%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$18.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Revenue: $44.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Report this figure(23.7%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$11.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Revenue: $48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure
Net margin%1.8%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $941.0k. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Revenue: $51.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Report this figure16.8%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $9.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Revenue: $57.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Report this figure(27.5%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$11.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Revenue: $41.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Report this figure(12.2%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$5.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Revenue: $45.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure(10.5%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$5.5m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Revenue: $52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049697.Report this figure(70.9%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$44.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Revenue: $62.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Report this figure(42.7%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$18.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Revenue: $44.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Report this figure(25.3%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$12.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Revenue: $48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053496.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m12.2Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $13.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001628280-25-049697. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001628280-25-049697. Derived: 9-month figure less the 6-month figure.Report this figure1.1Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Capital expenditure: $894.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Report this figure(1.0)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$125.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Capital expenditure: $849.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Report this figure(1.5)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $108.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053496. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001628280-26-053496. Derived: 6-month figure less the 3-month figure.Report this figure(4.6)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001628280-25-049697. Derived: 9-month figure less the 6-month figure.Capital expenditure: $657.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001628280-25-049697. Derived: 9-month figure less the 6-month figure.Report this figure(1.8)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$771.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012352. Derived: 12-month figure less the 9-month figure.Report this figure(4.9)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$2.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Capital expenditure: $2.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-032293.Report this figure(0.8)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053496. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001628280-26-053496. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$201.5mGross margin 51.8%
Diluted EPS−$0.09, FY2023
Free cash flow−$8.8m, FY2025
Cytek Biosciences, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m128Revenue, FY2021, twelve months to 2021-12-31$128.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-13, accession 0001628280-24-010933.Report this figure164Revenue, FY2022, twelve months to 2022-12-31$164.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0001628280-25-008780.Report this figure193Revenue, FY2023, twelve months to 2023-12-31$193.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure200Revenue, FY2024, twelve months to 2024-12-31$200.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure201Revenue, FY2025, twelve months to 2025-12-31$201.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure
Gross margin%61.9%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $79.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-13, accession 0001628280-24-010933.Revenue: $128.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-13, accession 0001628280-24-010933.Report this figure61.6%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $101.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-02-28, accession 0001628280-25-008780.Revenue: $164.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0001628280-25-008780.Report this figure56.7%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $109.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-012352.Revenue: $193.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure55.4%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $111.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-012352.Revenue: $200.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure51.8%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $104.5m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-012352.Revenue: $201.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure
Operating margin%7.2%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $9.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-13, accession 0001628280-24-010933.Revenue: $128.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-13, accession 0001628280-24-010933.Report this figure(1.1%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-28, accession 0001628280-25-008780.Revenue: $164.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0001628280-25-008780.Report this figure(14.4%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$27.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012352.Revenue: $193.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure(10.2%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$20.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012352.Revenue: $200.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure(20.0%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$40.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012352.Revenue: $201.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure
Net margin%2.4%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-13, accession 0001628280-24-010933.Revenue: $128.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-13, accession 0001628280-24-010933.Report this figure1.5%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $2.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-28, accession 0001628280-25-008780.Revenue: $164.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0001628280-25-008780.Report this figure(6.3%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$12.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012352.Revenue: $193.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure(3.0%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012352.Revenue: $200.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure(33.0%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$66.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012352.Revenue: $201.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure
Diluted EPS$ per share0.00Diluted EPS, FY2021, twelve months to 2021-12-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-13, accession 0001628280-24-010933.Report this figure0.02Diluted EPS, FY2022, twelve months to 2022-12-31$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-13, accession 0001628280-24-010933.Report this figure(0.09)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-13, accession 0001628280-24-010933.Report this figurenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m0.3Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-13, accession 0001628280-24-010933.Capital expenditure: $4.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-13, accession 0001628280-24-010933.Report this figure(22.0)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$12.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-28, accession 0001628280-25-008780.Capital expenditure: $9.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-28, accession 0001628280-25-008780.Report this figure0.6Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012352.Capital expenditure: $4.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure21.9Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $25.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012352.Capital expenditure: $3.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure(8.8)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$4.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012352.Capital expenditure: $4.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012352.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Cytek Biosciences, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$42.4m9,578,643Reduced−7,428,626
MILLENNIUM MANAGEMENT LLC2026-06-30$41.4m9,338,010Added+3,046,212
Boston Partners2026-06-30$33.9m7,660,943Added+1,858,170
HHLR ADVISORS, LTD.2026-06-30$29.5m6,657,030Unchanged
Topline Capital Management, LLC2026-06-30$27.8m6,283,450Reduced−781,031
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$21.9m4,939,597Added+176,693
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$13.6m3,059,573Added+225,618
DIMENSIONAL FUND ADVISORS LP2026-06-30$11.6m2,616,257Reduced−47,072
STATE STREET CORP2026-06-30$11.4m2,566,121Reduced−1,557,627
GOLDMAN SACHS GROUP INC2026-06-30$9.6m2,167,515Reduced−177,220

Recent filings

All 458 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Cytek Biosciences, Inc., recent filings
FiledFormWhat it isAccession number
2026-09-2916:06 ET8-K5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001193125-26-407330
2026-08-2406:01 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-361705
2026-08-0517:06 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-053496
2026-08-0516:22 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-335212
2026-07-1516:15 ET8-K5.02 Departure or appointment of officers or directors0001193125-26-304789
2026-06-2516:32 ET8-K5.02 Departure or appointment of officers or directors0001193125-26-282871
2026-06-1616:06 ET8-K5.07 Shareholder vote results0001193125-26-272582
2026-06-0216:15 ET8-K5.02 Departure or appointment of officers or directors0001193125-26-253538
2026-05-0717:03 ET10-QQuarterly reportPeriod 2026-03-310001628280-26-032293
2026-05-0716:14 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-211948

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1831915
Tickers
CTKB
Exchange
Nasdaq
SIC code
3826 Laboratory Analytical Instruments
Sector
Technology
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.